Synthesis and Antiproliferative Activity in vitro of New 2-Aminobenzimidazole Derivatives. Part 2 [1]

• Autorzy: Nawrocka W. , Sztuba B. , Liszkiewicz H. , Kowalska M. , Wietrzyk J. , Nevozhai D. , Opolski A.
• Języki publikacji: EN

Abstrakty

EN

A series of 2-methylpyrimido[1,2-a]benzimidazole derivatives has been synthesized in the reactions of 2-aminobenzimidazole (1) with selected halogeno _-diketones: 1,1,1- trifluoro- 2, 1-chloro-1,1-difluoro- 3, 3-chloro-2,4-pentadione- 4 and with 4-fluorobenzoylacetone 5. 2-Aminobenzimidazole (1) in the reactions with _-chloro- and _- bromocinnamaldehyde gave Schiff bases 10 and 11 which have been subjected to reduction using NaBH4 and 3-benzylideno-1,2-dihydro- (12) and 3-benzylideno-1,2,9,10- tetrahydroimidazo[1,2-a]benzimidazole (13) were obtained. The structures 2-13 were identified by the results of elemental analysis and their IR, 1H NMR and MS spectra. Compounds 2-13 were examined for their antiproliferative activity in vitro against the cells of 3 human cancer cell lines, using SRB (sulphorhodamine B) or MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) technique. Four out of all tested compounds revealed cytotoxic activity in vitro.

Słowa kluczowe

EN

2-aminobenzimidazole; halogeno-1,3-diketone; pyrimido[1,2-a]benzimidazole; imidazo[1,2-a]benzimidazole; antiproliferative activity in vitro

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2005
• Tom: Vol. 79 / nr 4
• Strony: 709--716
• Opis fizyczny: Bibliogr. 31 poz., rys.

Twórcy

autor

Nawrocka W.

• Department of Technology of Drugs, Wrocław University of Medicine,50-140 Wrocław, Nankier Sq. 1, Poland

autor

Sztuba B.

• Department of Physical Chemistry, Wroc³aw University of Medicine, 50-140 Wroc³aw, Nankier Sq. 1, Poland

autor

Liszkiewicz H.

• Department of Technology of Drugs, Wrocław University of Medicine,50-140 Wrocław, Nankier Sq. 1, Poland

autor

Kowalska M.

• Faculty of Chemistry, University of Wrocław, 50-383 Wrocław, Joliot-Curie Str. 14, Poland

autor

Wietrzyk J.

• Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, R. Weigla Str. 12, Poland

autor

Nevozhai D.

• Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, R. Weigla Str. 12, Poland

autor

Opolski A.

• Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, R. Weigla Str. 12, Poland

Bibliografia

• 1.Nawrocka W., Sztuba B., Kowalska W.M., Liszkiewicz H., Wietrzyk J., Nasulewicz A., Pelczynska M and Opolski A., Farmaco, 54, 83 (2004).
• 2.Bastrop J.A., Richards C.G., Russel D.H. and Ryback G., J. Chem. Soc., 1132 (1959).
• 3.Halford J.C. and Fitsch R.M., J. Am. Chem. Soc., 85, 3354 (1963).
• 4.Staab H.A. and VOgtle R, Chem. Ber., 98, 2700 (1965).
• 5.Mannschrcck A., Rissmann G., Vogtle R and Wild D., Chem. Ber., 100, 335 (1967).
• 6.Nawojski A. and Nawrocka W,,Ann. Soc. Chim. Polonarum, 48, 1073 (1974).
• 7.Liszkiewicz H., Kowalska M.W., Glowiak T., Wietrzyk J. and Opolski A., Polish J. Chem., 76, 160' (2002).
• 8.Nawojski A., Prace Naukowe Akademii Medycznej we Wrodawiu, Akademia Medyczna, Wroclaw 5(10) (1969); (in Polish).
• 9.Schmidt U. and Kubitzek H., Chem. Ber., 93, 1559 (1960).
• 10.Joshi K.C. and Chand P., Heterocycles, 16, 43 (1981).
• 11.Joshi K.C., Dubey K. and Dandia A., Heterocycles, 16, 1545 (1981).
• 12.Joshi K.C. and Chand P., J. Heterocyclic Chem., 17, 1783 (1980).
• 13.Lancelot J.C., Laduree D., El-Kashef H. and Robba M., Heterocycles, 23, 909 (1985).
• 14.Joshi K.C., Jain R., Dandia A. and Sharma K., J. Heterocyclic Chem., 25, 1641 (1988).
• 15.Nawrocka W„ Polish J. Chem., 68, 2659 (1994).
• 16.Nawrocka W., D.Sc. Thesis Wroclaw University of Medicine, Wroclaw 1999.
• 17.Nawrocka W. and Zimecki M., Arch. Pharm. Pharm. Med. Chem., 331, 249 (1998).
• 18.Nawrocka W., Zimecki M., Kuznicki T. and Kowalska MW., Arch. Pharm. Pharm. Med. Chem., 332, 85 (1999).
• 19.Seth P.P., Jefferson E.A., Riesen L.M. and Osgood S.A., Bioorg. Med. Chem. Lett., 13, 1669 (2003).
• 20.Asobo P.R, Wahe H., Mbafor J.T., Nkengfack A.E., Fomum Z.T., Sopbue E.F. and DiSpp D., Perkin Trans., 1,457 (2001).
• 21.Niva T., Katagiri S. and Kato T., Jpn. Kokai Tokkyo Koho JP 61 63,680 [86 63,680] (1986); C.A. 105. 172498w (1986).
• 22.Nikolova D., Ivanov R, Buyukliev S., Konstantinov M. and Karaivanova M., Arzneim.-Forsch. Drug Res., 51, 758 (2001).
• 23.Gerger C.J., Agy in J.K. and Quada J.C. Jr.; U.S. US 6407131B1 18 Jun 2002; C.A. 137,3330 lz (2002).
• 24.Gerger C.J., Agyin J.K. and Quada J.C. Jr.; U.S. USA6420411 B1 16 Jul 2002; C.A. 137,93753h (2002).
• 25.Jia L., Wong H., Wang Y., Garza M. and Weitman S.D., J. Pharm. Sci., 91, 161 (2003).
• 26.Rastogi R. and Sharma S., Synthesis, 861 (1983).
• 27.Nawrocka., Bull. Chim. Farmaceutico, 135, 281 (1996).
• 28.Mastalerz P., Chemia organiczna. Mechanizmy reakcji. 1970, WNT Warszawa, (in Polish).
• 29.Nawrocka W., Liszkiewicz H., Opolski A. and Wietrzyk J., P 362880, 2003.
• 30.Nawrocka W., Liszkiewicz H., Opolski A. and Wietrzyk J., P 362959, 2003.
• 31.Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesh H., Kenney S. and Boyol M.R., J. Natl. Cancer. Inst., 82, 1107 (1990).